BR122017021516B8 - processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia - Google Patents
processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula iaInfo
- Publication number
- BR122017021516B8 BR122017021516B8 BR122017021516A BR122017021516A BR122017021516B8 BR 122017021516 B8 BR122017021516 B8 BR 122017021516B8 BR 122017021516 A BR122017021516 A BR 122017021516A BR 122017021516 A BR122017021516 A BR 122017021516A BR 122017021516 B8 BR122017021516 B8 BR 122017021516B8
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- formula
- propylene glycol
- crystal structure
- solvate crystal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
a presente invenção refere-se às estruturas de cristal físicas de um composto da fórmula i: em que r1, r2, r2a, r3 e r4 são como definidos aqui, especialmente composições farmacêuticas que contêm estruturas de com-posto i ou ii, processos para preparar as mesmas, intermediários utilizados na preparação do mesmo, e métodos de tratar doenças tal como diabetes utilizando tal estrutura.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81711806P | 2006-06-28 | 2006-06-28 | |
US60/817,118 | 2006-06-28 | ||
US11/765,481 | 2007-06-20 | ||
US11/765,481 US7919598B2 (en) | 2006-06-28 | 2007-06-20 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
PCT/US2007/071749 WO2008002824A1 (en) | 2006-06-28 | 2007-06-21 | Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes |
BRPI0713544A BRPI0713544B8 (pt) | 2006-06-28 | 2007-06-21 | estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia |
Publications (2)
Publication Number | Publication Date |
---|---|
BR122017021516B1 BR122017021516B1 (pt) | 2021-03-16 |
BR122017021516B8 true BR122017021516B8 (pt) | 2021-07-27 |
Family
ID=38581970
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0713544A BRPI0713544B8 (pt) | 2006-06-28 | 2007-06-21 | estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia |
BR122017015106A BR122017015106B8 (pt) | 2006-06-28 | 2007-06-21 | estrutura de cristal de formula 1b e composição farmacêutica |
BR122017021516A BR122017021516B8 (pt) | 2006-06-28 | 2007-06-21 | processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0713544A BRPI0713544B8 (pt) | 2006-06-28 | 2007-06-21 | estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia |
BR122017015106A BR122017015106B8 (pt) | 2006-06-28 | 2007-06-21 | estrutura de cristal de formula 1b e composição farmacêutica |
Country Status (33)
Country | Link |
---|---|
US (3) | US7919598B2 (pt) |
EP (4) | EP3045466B1 (pt) |
JP (6) | JP5313889B2 (pt) |
KR (1) | KR101493102B1 (pt) |
CN (2) | CN103145773B (pt) |
AR (1) | AR061730A1 (pt) |
AU (1) | AU2007265246B2 (pt) |
BR (3) | BRPI0713544B8 (pt) |
CA (3) | CA2985797A1 (pt) |
CL (1) | CL2007001915A1 (pt) |
CO (1) | CO6160299A2 (pt) |
CY (1) | CY1115738T1 (pt) |
DK (1) | DK2069374T4 (pt) |
EA (4) | EA035999B1 (pt) |
ES (3) | ES2659862T3 (pt) |
HK (1) | HK1127359A1 (pt) |
HR (1) | HRP20141007T4 (pt) |
IL (5) | IL195882A (pt) |
MX (3) | MX339143B (pt) |
MY (2) | MY148566A (pt) |
NO (2) | NO346828B1 (pt) |
NZ (4) | NZ574346A (pt) |
PE (2) | PE20120776A1 (pt) |
PH (1) | PH12012500168A1 (pt) |
PL (1) | PL2069374T5 (pt) |
PT (1) | PT2069374E (pt) |
RS (1) | RS53638B2 (pt) |
SG (2) | SG172741A1 (pt) |
SI (1) | SI2069374T2 (pt) |
TW (4) | TW201546054A (pt) |
UA (1) | UA96765C2 (pt) |
WO (1) | WO2008002824A1 (pt) |
ZA (1) | ZA200810475B (pt) |
Families Citing this family (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7541357B2 (en) | 2004-07-15 | 2009-06-02 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
TW200726755A (en) * | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
MX2009006444A (es) * | 2006-12-21 | 2009-06-26 | Astellas Pharma Inc | Metodo para producir derivado de c-glucosido e intermediario sintetico del mismo. |
AR065809A1 (es) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
TW200904454A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
WO2008144346A2 (en) * | 2007-05-18 | 2008-11-27 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for their preparation |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
CN103319445B (zh) * | 2007-12-27 | 2016-01-20 | 阿斯利康公司 | Sglt2抑制剂的晶体结构及其制备方法 |
CN104387354A (zh) * | 2007-12-27 | 2015-03-04 | 阿斯利康公司 | Sglt2 抑制剂的晶体结构及其制备方法 |
MX2010007426A (es) * | 2008-01-31 | 2010-08-18 | Astellas Pharma Inc | Composiciones farmaceuticas para tratar trastorno del higado graso. |
WO2009117367A1 (en) * | 2008-03-18 | 2009-09-24 | Bristol-Myers Squibb Company | Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof |
US8603989B2 (en) * | 2008-05-22 | 2013-12-10 | Bristol-Myers Squibb Company | Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same |
CN102105153B (zh) * | 2008-05-22 | 2014-03-05 | 百时美施贵宝公司 | Sglt2抑制剂的医药用途和含该抑制剂的组合物 |
US8518895B2 (en) * | 2008-05-22 | 2013-08-27 | Bristol-Myers Squibb Company | Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
JP6071198B2 (ja) | 2008-07-15 | 2017-02-01 | テラコス,インコーポレーテッド | 重水素化ベンジルベンゼン誘導体及び使用方法 |
AU2014201286B2 (en) * | 2008-08-22 | 2015-07-02 | Theracosbio, Llc | Processes for the preparation of SGLT2 inhibitors |
NZ591818A (en) * | 2008-08-22 | 2013-01-25 | Theracos Inc | Processes for the preparation of sglt2 inhibitors |
JP4825322B1 (ja) | 2008-08-28 | 2011-11-30 | ファイザー・インク | ジオキサ−ビシクロ[3.2.1]オクタン−2,3,4−トリオール誘導体 |
WO2010092125A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
WO2010132487A1 (en) * | 2009-05-12 | 2010-11-18 | Bristol-Myers Squibb Company | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
CN102458123A (zh) * | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | 芳基、杂芳基和杂环取代的四氢异喹啉及其用途 |
PE20120373A1 (es) * | 2009-05-12 | 2012-05-17 | Albany Molecular Res Inc | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
PT2496583E (pt) | 2009-11-02 | 2015-01-14 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
CA2780939C (en) | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
AU2010319377B2 (en) | 2009-11-13 | 2014-10-23 | Astrazeneca Ab | Immediate release tablet formulations |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
JP2013523681A (ja) | 2010-03-30 | 2013-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Sglt2インヒビター及びppar−ガンマアゴニストを含む医薬組成物並びにその使用 |
CN108354930A (zh) | 2010-05-11 | 2018-08-03 | 詹森药业有限公司 | 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂 |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2012025857A1 (en) | 2010-08-23 | 2012-03-01 | Hetero Research Foundation | Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors |
US20130224296A1 (en) | 2010-09-03 | 2013-08-29 | Bristol-Myers Squibb Company | Drug Formulations Using Water Soluble Antioxidants |
WO2012041898A1 (en) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes |
US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
MX2013008372A (es) | 2011-02-01 | 2013-08-12 | Astrazeneca Uk Ltd | Formulaciones farmaceuticas que incluyen compuesto de amina. |
US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US10544135B2 (en) | 2011-04-13 | 2020-01-28 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
JP5835598B2 (ja) | 2011-06-03 | 2015-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 神経弛緩剤で治療されている患者において代謝性障害を治療するためのsglt−2阻害剤 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
BR112014010574A2 (pt) * | 2011-10-31 | 2017-05-02 | Scinopharm Taiwan Ltd | formas cristalinas e não cristalinas de inibidores sglt2 |
EP2597090A1 (en) | 2011-11-28 | 2013-05-29 | Sandoz AG | Crystalline dapagliflozin hydrate |
TW201335176A (zh) | 2011-12-15 | 2013-09-01 | Nat Health Research Institutes | 新穎醣苷化合物 |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
US9145434B2 (en) * | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
CN103910769B (zh) * | 2012-12-31 | 2018-10-02 | 上海璎黎药业有限公司 | 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用 |
CN103910719B (zh) * | 2012-12-31 | 2018-05-01 | 上海璎黎药业有限公司 | 葡萄糖衍生物与苯丙氨酸复合物、晶体、制备方法及应用 |
EP2968375B1 (en) | 2013-03-14 | 2019-06-12 | MSD International GmbH | Methods for preparing sglt2 inhibitors |
PL2981269T3 (pl) | 2013-04-04 | 2024-02-05 | Boehringer Ingelheim Vetmedica Gmbh | Leczenie zaburzeń metabolicznych u zwierząt koniowatych |
EP2991999B1 (en) | 2013-04-29 | 2019-05-08 | Mapi Pharma Limited | Dapagliflozin lactose co-crystal |
US20160214953A1 (en) | 2013-09-23 | 2016-07-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of dapagliflozin |
US20160237054A1 (en) | 2013-09-27 | 2016-08-18 | Sun Pharmaceutical Industries Limited | Process for the purification of dapagliflozin |
CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
US20160280619A1 (en) | 2013-10-31 | 2016-09-29 | Sun Pharmaceutical Industries Limited | Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene |
HUE053906T2 (hu) | 2013-12-17 | 2021-07-28 | Boehringer Ingelheim Vetmedica Gmbh | SGLT2-inhibitorok macskafélék közé tartozó állatok anyagcsere-rendellenességeinek kezelésére |
US10603300B2 (en) * | 2014-01-23 | 2020-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
CN104829572B (zh) * | 2014-02-10 | 2019-01-04 | 江苏豪森药业集团有限公司 | 达格列净新晶型及其制备方法 |
EP3110402A1 (en) | 2014-02-28 | 2017-01-04 | Sun Pharmaceutical Industries Ltd | Dapagliflozin compositions |
IN2014CH01141A (pt) * | 2014-03-06 | 2015-09-11 | Msn Lab Private Ltd | |
PT3125882T (pt) | 2014-04-01 | 2020-08-17 | Boehringer Ingelheim Vetmedica Gmbh | Tratamento de distúrbios metabólicos em animais equinos |
BR112016026809A2 (pt) | 2014-05-19 | 2017-12-12 | Pfizer | compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr |
CN104031098A (zh) * | 2014-06-21 | 2014-09-10 | 李友香 | 降糖药物 |
CN104017031A (zh) * | 2014-06-21 | 2014-09-03 | 李友香 | 降血糖药物和组合物 |
EP3229814A4 (en) * | 2014-06-23 | 2018-07-11 | Sun Pharmaceutical Industries Ltd | Co-crystal of dapagliflozin with citric acid |
KR20160013770A (ko) * | 2014-07-28 | 2016-02-05 | 한미정밀화학주식회사 | 다파글리프로진의 신규 결정질 복합체 및 이의 제조방법 |
KR102539788B1 (ko) | 2014-09-25 | 2023-06-07 | 베링거잉겔하임베트메디카게엠베하 | 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료 |
RU2695652C2 (ru) | 2014-09-25 | 2019-07-25 | Астразенека Аб | Комбинация омега-3 жирной кислоты и SGLT-2 ингибитора для лечения болезней печени |
CN104496952B (zh) * | 2014-11-28 | 2017-04-19 | 深圳翰宇药业股份有限公司 | 一种达格列净的合成方法 |
EP3226874A1 (en) * | 2014-12-03 | 2017-10-11 | Sun Pharmaceutical Industries Ltd | Processes for the preparation of ertugliflozin |
CZ2015110A3 (cs) * | 2015-02-18 | 2016-08-31 | Zentiva, K.S. | Pevné formy empagliflozinu |
WO2016147197A1 (en) * | 2015-03-17 | 2016-09-22 | Harman Finochem Limited | A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form |
WO2016155578A1 (zh) * | 2015-03-27 | 2016-10-06 | 苏州晶云药物科技有限公司 | 达格列净的新晶型及其制备方法 |
WO2016161995A1 (en) | 2015-04-08 | 2016-10-13 | Zentiva, K.S. | Solid forms of amorphous dapagliflozin |
CN106146446B (zh) * | 2015-04-17 | 2019-11-08 | 杭州领业医药科技有限公司 | 达格列净半水合物及其晶型、其制备方法及药物组合物 |
US10556877B2 (en) | 2015-05-05 | 2020-02-11 | Glenmark Life Sciences Limited | Process for preparation of dapagliflozin |
CN107921021A (zh) | 2015-06-17 | 2018-04-17 | 大塚制药美国公司 | 结晶化合物 |
WO2017042683A1 (en) * | 2015-09-07 | 2017-03-16 | Dr. Reddy's Laboratories Limited | Isolated intermediate of dapagliflozin, process for the preparation of isolated intermediate of dapagliflozin, process for the preparation of dapagliflozin |
ES2896101T3 (es) | 2015-09-15 | 2022-02-23 | Laurus Labs Ltd | Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos |
WO2017060925A1 (en) * | 2015-10-09 | 2017-04-13 | Harman Finochem Limited | Novel pipecolic acid co-crystals of dapagliflozin and process for the preparation thereof |
US9845303B2 (en) | 2015-10-19 | 2017-12-19 | Cadila Healthcare Limited | Process for the preparation of dapagliflozin |
US10555930B2 (en) * | 2015-11-27 | 2020-02-11 | North & South Brother Pharmacy Investment Company Limited | Complex of a glucopyranosyl derivative and preparation method and use thereof |
KR102004488B1 (ko) * | 2015-12-11 | 2019-07-26 | 동아에스티 주식회사 | 다파글리플로진의 신규 용매화물 및 이의 제조방법 |
WO2017118945A1 (en) | 2016-01-08 | 2017-07-13 | Lupin Limited | Premix of dapagliflozin and process for the preparation thereof |
CN105503802A (zh) * | 2016-01-15 | 2016-04-20 | 中山大学 | 一种达格列净-柠檬酸共晶的制备方法 |
EP3426256A4 (en) | 2016-03-11 | 2019-11-06 | Merck Sharp & Dohme Corp. | METHOD OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND DISEASES ASSOCIATED WITH SGLT-2 INHIBITOR |
MX2018011696A (es) | 2016-03-31 | 2019-06-06 | Lupin Ltd | Composición farmacéutica de dapagliflozina. |
US10759772B2 (en) * | 2016-05-02 | 2020-09-01 | Aurobindo Pharma Ltd | Process for the preparation of DL-proline co-crystal of Dapagliflozin |
JP7007300B2 (ja) * | 2016-05-24 | 2022-01-24 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ダパグリフロジンの新規な結晶形並びにその製造方法および用途 |
WO2017203457A1 (en) * | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Solid state forms of empagliflozin |
WO2017203229A1 (en) | 2016-05-27 | 2017-11-30 | Cipla Limited | Dapagliflozin premixes |
WO2017206827A1 (zh) * | 2016-05-28 | 2017-12-07 | 山东轩竹医药科技有限公司 | 钠-葡萄糖协同转运蛋白2抑制剂的晶型 |
CN107445932A (zh) * | 2016-05-30 | 2017-12-08 | 上海医药工业研究院 | 达格列净共晶物的制备工艺 |
WO2017221211A1 (en) * | 2016-06-24 | 2017-12-28 | Biocon Limited | Process for the preparation of dapagliflozin and its solvate thereof |
CN107641139A (zh) | 2016-07-22 | 2018-01-30 | 江苏豪森药业集团有限公司 | 达格列净中间体的晶型及其制备方法 |
EA201990951A1 (ru) | 2016-10-19 | 2019-11-29 | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
KR20180058510A (ko) * | 2016-11-24 | 2018-06-01 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 |
KR20180078762A (ko) * | 2016-12-30 | 2018-07-10 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물 |
WO2018124497A1 (ko) | 2016-12-30 | 2018-07-05 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제 |
WO2018167589A1 (en) | 2017-03-16 | 2018-09-20 | Inventia Healthcare Private Limited | Pharmaceutical composition comprising dapagliflozin |
TWI797133B (zh) | 2017-06-09 | 2023-04-01 | 丹麥商諾佛 儂迪克股份有限公司 | 用於經口投予的固體組成物 |
CN107488156B (zh) * | 2017-09-04 | 2020-05-26 | 上海现代制药股份有限公司 | 一种无定型葡萄糖醇的合成方法 |
WO2019066359A2 (ko) * | 2017-09-29 | 2019-04-04 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제 |
KR102369679B1 (ko) * | 2017-09-29 | 2022-03-04 | 한미약품 주식회사 | 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제 |
CN108516966A (zh) * | 2017-10-19 | 2018-09-11 | 浙江海正药业股份有限公司 | 达格列净的晶型及其制备方法和用途 |
KR20190115948A (ko) | 2018-04-04 | 2019-10-14 | 한미약품 주식회사 | 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물 |
AU2019254371A1 (en) | 2018-04-17 | 2020-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
KR102204439B1 (ko) | 2018-05-14 | 2021-01-18 | 에이치케이이노엔 주식회사 | Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물 |
MX2021000601A (es) | 2018-07-19 | 2021-04-13 | Astrazeneca Ab | Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma. |
WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
SG11202102498UA (en) * | 2018-09-26 | 2021-04-29 | Lexicon Pharmaceuticals Inc | Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis |
EA202190841A1 (ru) | 2018-10-01 | 2021-07-15 | Астразенека Аб | Композиции для снижения уровней мочевой кислоты в сыворотке крови |
CN109705075B (zh) * | 2018-12-13 | 2022-12-23 | 苏中药业集团股份有限公司 | 一种达格列净的纯化方法 |
CN109705076B (zh) * | 2019-01-21 | 2023-03-24 | 苏中药业集团股份有限公司 | 一种达格列净晶型、制备方法及其用途 |
CN111559997A (zh) * | 2019-02-13 | 2020-08-21 | 罗欣药业(上海)有限公司 | 一种达格列净新晶型及其制备方法 |
CN111689936A (zh) * | 2019-03-15 | 2020-09-22 | 罗欣药业(上海)有限公司 | 达格列净新晶型及其制备方法 |
WO2021089752A1 (en) | 2019-11-07 | 2021-05-14 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
MX2019014226A (es) * | 2019-11-27 | 2022-09-23 | Alparis Sa De Cv | Nuevas fases sólidas de dapagliflozina. |
EP4064854A1 (en) | 2019-11-28 | 2022-10-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors in the drying-off of non-human mammals |
AU2020413580A1 (en) * | 2019-12-24 | 2022-06-30 | Hanmi Pharm. Co., Ltd. | Complex formulation comprising sitagliptin and dapagliflozin, and preparation method therefor |
EP4106744A1 (en) | 2020-02-17 | 2022-12-28 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
WO2021165316A1 (en) | 2020-02-21 | 2021-08-26 | Zakłady Farmaceutyczne POLPHARMA S.A. | Pharmaceutical composition comprising dapagliflozin |
WO2021176096A1 (en) | 2020-03-05 | 2021-09-10 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising sglt2 inhibitor |
CN115916197A (zh) | 2020-04-22 | 2023-04-04 | 拜耳公司 | 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合 |
US20230165856A1 (en) | 2020-04-29 | 2023-06-01 | Astrazeneca Ab | Dapagliflozin and ambrisentan for the prevention and treatment of covid-19 |
KR20220007446A (ko) * | 2020-07-10 | 2022-01-18 | 한미약품 주식회사 | 시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법 |
US20220023252A1 (en) | 2020-07-27 | 2022-01-27 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
CN116249699A (zh) * | 2020-09-30 | 2023-06-09 | 北京睿创康泰医药研究院有限公司 | 一种sglt-2抑制剂·肌氨酸共晶体及其制备方法和应用 |
EP4376830A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
WO2023006718A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
WO2023006745A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
CN114394993B (zh) * | 2021-11-11 | 2023-11-10 | 苏州正济药业有限公司 | 一种达格列净中间体的制备方法 |
CN114213399A (zh) * | 2021-12-20 | 2022-03-22 | 上海启讯医药科技有限公司 | 一种卡格列净丙酮水合物及其制备方法和用途 |
WO2023129595A1 (en) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | Obicetrapib and sglt2 inhibitor combination |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2023227492A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
WO2024033519A1 (en) | 2022-08-12 | 2024-02-15 | Astrazeneca Ab | Combination therapies for treatment of cirrhosis with portal hypertension |
WO2024047574A1 (en) | 2022-09-01 | 2024-03-07 | Astrazeneca Ab | Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases |
WO2024062310A1 (en) * | 2022-09-22 | 2024-03-28 | Savoi Guilherme | Co-crystals derived from empagliflozin and dapagliflozin with l-proline |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5612114B2 (pt) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
HU198005B (en) | 1984-12-04 | 1989-07-28 | Sandoz Ag | Process for producing mevqlolakton, derivatives, its indene-analogues and pharmaceutical compositions containing them |
US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
HUT48208A (en) | 1985-10-25 | 1989-05-29 | Sandoz Ag | Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds |
FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
NZ224733A (en) | 1987-05-22 | 1990-12-21 | Squibb & Sons Inc | Organophosphorus hmg-coa reductase inhibitors; intermediates and compositions thereof |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
US5712396A (en) | 1992-10-28 | 1998-01-27 | Magnin; David R. | α-phosphonosulfonate squalene synthetase inhibitors |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
EP0680320B1 (en) | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
US5340583A (en) | 1993-05-06 | 1994-08-23 | Allergan, Inc. | Antimicrobial lenses and lens care systems |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
ATE344279T1 (de) | 1995-12-13 | 2006-11-15 | Univ California | Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
EP1052994A2 (en) | 1998-02-02 | 2000-11-22 | Trustees Of Tufts College | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
AU3034299A (en) | 1998-03-09 | 1999-09-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
GB9807354D0 (en) * | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE69940063D1 (de) | 1998-07-06 | 2009-01-22 | Bristol Myers Squibb Co | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin |
US6069238A (en) | 1998-09-30 | 2000-05-30 | Eli Lilly And Company | Spirocyclic C-glycosides |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
TW200528436A (en) | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
KR20020014570A (ko) * | 2000-08-18 | 2002-02-25 | 김충섭 | 고체분산화시킨 무정형 이프리플라본의 제조방법 |
US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
ES2258141T3 (es) * | 2001-04-11 | 2006-08-16 | Bristol-Myers Squibb Company | Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento. |
JP2004530703A (ja) * | 2001-05-22 | 2004-10-07 | ファイザー・プロダクツ・インク | 結晶形アジスロマイシン |
IL160917A0 (en) | 2001-10-18 | 2004-08-31 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
WO2004060347A2 (en) † | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
WO2004061433A1 (en) * | 2002-12-30 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
AU2003243354A1 (en) * | 2002-05-31 | 2003-12-19 | Transform Pharmaceuticals, Inc. | Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods |
US7375213B2 (en) * | 2003-01-03 | 2008-05-20 | Bristol-Myers Squibb Company | Methods of producing C-aryl glucoside SGLT2 inhibitors |
US7164015B2 (en) | 2003-02-27 | 2007-01-16 | Bristol-Myers Squibb Company | Non-cryogenic process for forming glycosides |
WO2004080990A1 (ja) * | 2003-03-14 | 2004-09-23 | Astellas Pharma Inc. | C-グリコシド誘導体又はその塩 |
EP1595880A1 (en) * | 2004-05-13 | 2005-11-16 | Speedel Pharma AG | Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists |
RU2364596C2 (ru) * | 2004-06-11 | 2009-08-20 | Джапан Тобакко Инк. | ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
CN104829572B (zh) | 2014-02-10 | 2019-01-04 | 江苏豪森药业集团有限公司 | 达格列净新晶型及其制备方法 |
-
2007
- 2007-06-20 US US11/765,481 patent/US7919598B2/en active Active
- 2007-06-21 BR BRPI0713544A patent/BRPI0713544B8/pt active IP Right Grant
- 2007-06-21 EP EP15181545.3A patent/EP3045466B1/en active Active
- 2007-06-21 SG SG2011047727A patent/SG172741A1/en unknown
- 2007-06-21 MY MYPI20085336A patent/MY148566A/en unknown
- 2007-06-21 JP JP2009518468A patent/JP5313889B2/ja active Active
- 2007-06-21 NO NO20085169A patent/NO346828B1/no unknown
- 2007-06-21 EP EP07784499.1A patent/EP2069374B2/en active Active
- 2007-06-21 PL PL07784499T patent/PL2069374T5/pl unknown
- 2007-06-21 WO PCT/US2007/071749 patent/WO2008002824A1/en active Application Filing
- 2007-06-21 MX MX2011009646A patent/MX339143B/es unknown
- 2007-06-21 RS RS20140570A patent/RS53638B2/sr unknown
- 2007-06-21 NZ NZ574346A patent/NZ574346A/en unknown
- 2007-06-21 DK DK07784499.1T patent/DK2069374T4/da active
- 2007-06-21 MX MX2016006205A patent/MX367155B/es unknown
- 2007-06-21 BR BR122017015106A patent/BR122017015106B8/pt active IP Right Grant
- 2007-06-21 UA UAA200900606A patent/UA96765C2/uk unknown
- 2007-06-21 PT PT77844991T patent/PT2069374E/pt unknown
- 2007-06-21 EP EP17203302.9A patent/EP3363807B1/en active Active
- 2007-06-21 AU AU2007265246A patent/AU2007265246B2/en active Active
- 2007-06-21 CN CN201310052369.2A patent/CN103145773B/zh active Active
- 2007-06-21 ES ES15181545.3T patent/ES2659862T3/es active Active
- 2007-06-21 NZ NZ589202A patent/NZ589202A/en unknown
- 2007-06-21 CN CN200780024135XA patent/CN101479287B/zh active Active
- 2007-06-21 ES ES17203302T patent/ES2769130T3/es active Active
- 2007-06-21 BR BR122017021516A patent/BR122017021516B8/pt active IP Right Grant
- 2007-06-21 CA CA2985797A patent/CA2985797A1/en not_active Abandoned
- 2007-06-21 ES ES07784499T patent/ES2521665T5/es active Active
- 2007-06-21 SG SG10201402181SA patent/SG10201402181SA/en unknown
- 2007-06-21 EP EP12152907A patent/EP2457918A3/en not_active Withdrawn
- 2007-06-21 NZ NZ589195A patent/NZ589195A/en unknown
- 2007-06-21 CA CA2653344A patent/CA2653344C/en active Active
- 2007-06-21 EA EA201791254A patent/EA035999B1/ru not_active IP Right Cessation
- 2007-06-21 EA EA201171333A patent/EA020428B1/ru not_active IP Right Cessation
- 2007-06-21 CA CA2924318A patent/CA2924318C/en active Active
- 2007-06-21 MY MYPI2014001983A patent/MY173930A/en unknown
- 2007-06-21 NZ NZ589190A patent/NZ589190A/en unknown
- 2007-06-21 EA EA200900066A patent/EA018229B1/ru not_active IP Right Cessation
- 2007-06-21 EA EA201490902A patent/EA028259B1/ru not_active IP Right Cessation
- 2007-06-21 KR KR1020087031643A patent/KR101493102B1/ko active IP Right Review Request
- 2007-06-21 SI SI200731535T patent/SI2069374T2/sl unknown
- 2007-06-21 MX MX2008015377A patent/MX2008015377A/es active IP Right Grant
- 2007-06-28 TW TW104129264A patent/TW201546054A/zh unknown
- 2007-06-28 TW TW103140880A patent/TWI519528B/zh not_active IP Right Cessation
- 2007-06-28 TW TW102137967A patent/TWI466876B/zh not_active IP Right Cessation
- 2007-06-28 CL CL2007001915A patent/CL2007001915A1/es unknown
- 2007-06-28 AR ARP070102896A patent/AR061730A1/es not_active Application Discontinuation
- 2007-06-28 TW TW096123519A patent/TWI421245B/zh not_active IP Right Cessation
- 2007-07-02 PE PE2011001791A patent/PE20120776A1/es not_active Application Discontinuation
- 2007-07-02 PE PE2007000845A patent/PE20080349A1/es not_active Application Discontinuation
-
2008
- 2008-11-10 ZA ZA2008/10475A patent/ZA200810475B/en unknown
- 2008-12-11 IL IL195882A patent/IL195882A/en active IP Right Grant
- 2008-12-24 CO CO08136743A patent/CO6160299A2/es unknown
-
2009
- 2009-07-16 HK HK09106471.6A patent/HK1127359A1/xx active IP Right Maintenance
-
2011
- 2011-03-16 US US13/049,712 patent/US8501698B2/en active Active
- 2011-07-19 IL IL214181A patent/IL214181A/en active IP Right Grant
- 2011-07-19 IL IL214182A patent/IL214182A/en active IP Right Grant
- 2011-07-19 IL IL214180A patent/IL214180A/en active IP Right Grant
-
2012
- 2012-01-26 PH PH12012500168A patent/PH12012500168A1/en unknown
-
2013
- 2013-05-14 JP JP2013102220A patent/JP5666651B2/ja active Active
- 2013-07-10 US US13/938,763 patent/US9453039B2/en active Active
-
2014
- 2014-10-21 HR HRP20141007TT patent/HRP20141007T4/hr unknown
- 2014-10-29 CY CY20141100887T patent/CY1115738T1/el unknown
- 2014-12-10 JP JP2014250141A patent/JP5937187B2/ja active Active
-
2016
- 2016-05-11 JP JP2016095472A patent/JP2016172758A/ja active Pending
- 2016-05-17 IL IL245688A patent/IL245688A0/en unknown
-
2017
- 2017-07-07 JP JP2017133952A patent/JP2017222681A/ja active Pending
-
2018
- 2018-12-18 JP JP2018236514A patent/JP2019059779A/ja active Pending
-
2022
- 2022-11-17 NO NO20221233A patent/NO347770B1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR122017021516B8 (pt) | processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia | |
ECSP088765A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
NI201100081A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes. | |
BR112012027062B8 (pt) | composto, processo para a preparação de um composto e usos do mesmo | |
UY32648A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades | |
BRPI0911035B8 (pt) | ativadores de pirrolidinona glicoquinase | |
UY32958A (es) | Derivados de glicósido y usos de los mismos. | |
BRPI0910388A2 (pt) | agentes terapêutico antivirais. | |
DOP2009000148A (es) | Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides | |
BRPI0910439B8 (pt) | derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos | |
CO6270324A2 (es) | Derivados de pirimidina para el tratamiento del asma epoc rinitis conjutivitis alergica dermatitis atopica cancer hepatitis b hepatitis c vih vph infecciones bacterianas y dermatosis | |
BRPI0911476A2 (pt) | compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos | |
UY29002A1 (es) | Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
BRPI0915592A2 (pt) | composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii | |
BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
ECSP088891A (es) | Derivados bicíclicos como inhibidores de cetp | |
BRPI0910832B8 (pt) | derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos. | |
UY29003A1 (es) | Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia | |
BR112014019622B8 (pt) | composto, seus usos, composição pesticida, material de propagação de plantas tratado e composições farmacêuticas | |
CO6331470A2 (es) | Antogonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
ECSP099425A (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2 | |
UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
BRPI0908569B8 (pt) | estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica | |
BRPI0713951B8 (pt) | derivados de quinazolina, e composição farmacêutica | |
UY30862A1 (es) | Derivados de piridopirimidina, composiciones farmacéuticas conteniéndolos, procesos de preparacioon y aplicaciones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/06/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |